⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Sunshine Guojian is a leading Chinese biopharmaceutical company specializing in the research, development, industrialization, and commercialization of innovative therapeutic antibody drugs. Established in 2002, it focuses on providing high-quality clinical solutions for major diseases, particularly in the fields of autoimmune diseases and oncology.
The company is a subsidiary of 3SBio Inc. and operates as a high-tech enterprise with advanced R&D and manufacturing capabilities. It has a robust pipeline of antibody drug candidates and maintains a strong focus on innovation, international cooperation, and patient-centered drug development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Founded:2002
Ownership:public
Status:operating
STOCK
Exchange:Shanghai Stock Exchange
Ticker:688336
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Monoclonal antibodies, Bispecific antibodies
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:3SBio Inc.
Key Partnerships:Pfizer (Global licensing agreement for SSGJ-707, May 2025), Numab Therapeutics (Development of multi-specific antibodies)
COMPETITION
Position:Leader
LINKS
Website:3s-guojian.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.